Skip to main content
. Author manuscript; available in PMC: 2023 Jul 21.
Published in final edited form as: Circ Res. 2022 Feb 17;130(4):436–454. doi: 10.1161/CIRCRESAHA.121.319900

Table 2.

Sex Differences in Risk of Mortality and/or Hospitalization in Heart Failure with Preserved Ejection Fraction

Study Endpoint Risk (95% CI)
Women Men
ARNI
 PARAGON-HF91 CV Mortality or HF Hospitalization RR 0.73 (0.59–0.90) RR 1.03 (0.85–1.25)
Aldosterone blockers
 TOPCAT90 CV Mortality or HF hospitalization aHR 0.81 (0.63–1.05) aHR 0.85(0.67–1.08)
SGLT2 inhibitors
 EMPEROR-Preserved94 CV Mortality or HF hospitalization HR 0.75 (0.61–0.92) HR 0.81 (0.69–0.96)